Article

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old

2022-03-24

Abstract excerpt

<title>Abstract</title> <p>The rapid emergence of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus-2 led to a global resurgence of coronavirus disease 2019 (Covid-19). Israeli authorities approved a 4th Covid-19 vaccine dose (second-booster) for individuals aged 60 and above who received a first booster dose four or more months earlier. Evidence regarding the effectiveness of a sec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6a4b4c3f-216f-510a-9227-e8db1ee5b5cc
DOI: 10.21203/rs.3.rs-1478439/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years OldDOI 10.21203/rs.3.rs-1478439/v1Read

Second Booster Vaccine Dose for Older Adults and COVID-19 Mortality During the Omicron SurgeSemantic proximity Read

Safety of the Fourth COVID-19 BNT162b2 mRNA (Second Booster) VaccineSemantic proximity Read

BNT162b2 vaccine booster dose protection: A nationwide study from IsraelSemantic proximity Read

Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adultsSemantic proximity Read

Real-world analysis of age-dependent efficacy of COVID-19 vaccinationSemantic proximity Read

Booster Vaccination Strongly Enhances SARS-CoV-2-Specific Antibody and Cellular Responses in Elderly Residents of Care HomesSemantic proximity Read

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised studySemantic proximity Read

Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022Semantic proximity Read

Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal studySemantic proximity Read

Safety and Immunogenicity of SARS-Cov-2 Vaccine MVC-COV1901– Do Elderly Need a Higher Dose?Semantic proximity Read

Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trialSemantic proximity Read

COVID-19 Vaccine Booster Significantly Decreases the Risk of Intensive Care Unit Hospitalization in Heart Failure Patients During the Omicron Variant Wave: A Population-Based StudySemantic proximity Read